Clinical Trial Update: GliaSite 1-3 Mets Study [Phase 2]

View source ↗

Summary

Phase 2 results for the GliaSite 1-3 Mets Study in patients with brain metastases have been completed. The sponsor is Hologic, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases

Snippet

Sponsor: Hologic, Inc. | Conditions: Brain Metastases | Phase 2 | Status: COMPLETED